Company intelligence / Profile preview

bBHC

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

bBHC is a South Korean biotech company developing novel cell therapies based on its proprietary KH cells (KHCs) platform. These KHCs, derived from umbilical cord mesenchymal stem cells via non-genetic reprogramming, are being investigated for their potential in cancer inhibition and anti-aging applications, exhibiting favorable safety profiles.

Therapeutic areas: OncologyOther
Modalities: Cell therapy
Industry: Biotech

Beyond the preview

Go deeper on bBHC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bBHC.

Explore the full profile